Advancing the Boundaries of Immunotherapy in Lung Adenocarcinoma with Idiopathic Pulmonary Fibrosis by a Biomimetic Proteinoid Enabling Selective Endocytosis
Aimin Jiang,
Xiaoqiang Zheng,
Siqi Yan
et al.
Abstract:The coexistence of lung adenocarcinoma (LUAD) with idiopathic pulmonary fibrosis (IPF), which has been extensively documented as a prominent risk factor for checkpoint inhibitor-related pneumonitis (CIP) in patients undergoing immunotherapy, has long been considered a restricted domain for the use of immune checkpoint inhibitors (ICIs). To overcome it, an approach was employed herein to specifically target PD-L1 within the cellular interior, surpassing the conventional focus solely on the cytomembrane, thereby… Show more
“…They concluded CM-NPs hold great potential as a pivotal drug delivery strategy in the diagnosis and treatment of various malignancies, including breast cancer. Recent studies have revealed that biomimetic nanoparticles derived from erythrocyte membranes exhibit excellent tumor-targeting capabilities by altering the endocytosis mechanism (6,21). A recent study has introduced an innovative approach by developing an erythrocyte membrane biomimetic ICI proteinoid to selectively inhibit tumor cell PD-L1 via a distinct endocytosis pathway between cancerous and non-cancerous cells (6).…”
Section: Zhou Et Al Reviewed Recent Advances In the Use Of Cancer Cel...mentioning
confidence: 99%
“…In vivo experiments have shown that the biomimetic ICI proteinoid not only reactivates the anti-tumor immune response in a murine model of lung adenocarcinoma with coexisting idiopathic pulmonary fibrosis but also demonstrates a favorable safety profile by effectively eliminating any irAEs. This breakthrough broadens the boundaries of immunotherapy in lung cancer treatment (6).…”
Section: Zhou Et Al Reviewed Recent Advances In the Use Of Cancer Cel...mentioning
Editorial on the Research TopicOvercoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine Targeting the immune system using checkpoint blockade antibodies and chimeric antigen receptor T-cell (CAR-T) therapy has proven to be a successful clinical approach for cancer immunotherapy (1). Despite significant advancements in this field, several persistent challenges remain that demand attention. In 2020, Hegde et al. delineated ten pivotal obstacles to cancer immunotherapy, spanning from uncertainties in translating preclinical findings to identifying the optimal combination therapies for specific patients (2). These challenges encompass enhancing treatment response rates, elucidating immune resistance mechanisms, conquering immunotherapy resistance, identifying and managing immune-related adverse events (irAEs), identifying reliable predictive biomarkers, determining optimal combination strategies, and crafting personalized treatment regimens based on the unique characteristics of each patient (Figure 1). Nanomedicine has recently emerged as a potentially revolutionary domain for innovating therapeutic approaches, particularly in the realm of cancer detection and treatment (3). In recent years, a growing body of nanoparticles with distinct properties has been developed to overcome the hurdles of cancer immunotherapy (4-6). This Research Topic in Frontiers in Oncology provides insightful information about the critical role of nanomedicine in addressing the challenges of cancer immunotherapy.Cancer immunotherapy faces a significant challenge in the form of treatment resistance, posing a major hurdle to its effectiveness. Studies have shown that approximately 30% of nonsmall cell lung cancer (NSCLC) patients exhibit resistance to initial immunotherapy, whether utilizing immune checkpoint inhibitors (ICI) alone or in combination with another ICI (7-10). Shao et al. conducted a review to explore the mechanisms underlying immunotherapy resistance and outlined recent breakthroughs in nanomedicine designed to combat this resistance. Tumor heterogeneity and complexity, characterized by intricate metabolic, inflammatory, and neovascular pathways, remain poorly understood yet prevalent contributors to immunotherapy resistance (11). Currently, immunotherapy
“…They concluded CM-NPs hold great potential as a pivotal drug delivery strategy in the diagnosis and treatment of various malignancies, including breast cancer. Recent studies have revealed that biomimetic nanoparticles derived from erythrocyte membranes exhibit excellent tumor-targeting capabilities by altering the endocytosis mechanism (6,21). A recent study has introduced an innovative approach by developing an erythrocyte membrane biomimetic ICI proteinoid to selectively inhibit tumor cell PD-L1 via a distinct endocytosis pathway between cancerous and non-cancerous cells (6).…”
Section: Zhou Et Al Reviewed Recent Advances In the Use Of Cancer Cel...mentioning
confidence: 99%
“…In vivo experiments have shown that the biomimetic ICI proteinoid not only reactivates the anti-tumor immune response in a murine model of lung adenocarcinoma with coexisting idiopathic pulmonary fibrosis but also demonstrates a favorable safety profile by effectively eliminating any irAEs. This breakthrough broadens the boundaries of immunotherapy in lung cancer treatment (6).…”
Section: Zhou Et Al Reviewed Recent Advances In the Use Of Cancer Cel...mentioning
Editorial on the Research TopicOvercoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine Targeting the immune system using checkpoint blockade antibodies and chimeric antigen receptor T-cell (CAR-T) therapy has proven to be a successful clinical approach for cancer immunotherapy (1). Despite significant advancements in this field, several persistent challenges remain that demand attention. In 2020, Hegde et al. delineated ten pivotal obstacles to cancer immunotherapy, spanning from uncertainties in translating preclinical findings to identifying the optimal combination therapies for specific patients (2). These challenges encompass enhancing treatment response rates, elucidating immune resistance mechanisms, conquering immunotherapy resistance, identifying and managing immune-related adverse events (irAEs), identifying reliable predictive biomarkers, determining optimal combination strategies, and crafting personalized treatment regimens based on the unique characteristics of each patient (Figure 1). Nanomedicine has recently emerged as a potentially revolutionary domain for innovating therapeutic approaches, particularly in the realm of cancer detection and treatment (3). In recent years, a growing body of nanoparticles with distinct properties has been developed to overcome the hurdles of cancer immunotherapy (4-6). This Research Topic in Frontiers in Oncology provides insightful information about the critical role of nanomedicine in addressing the challenges of cancer immunotherapy.Cancer immunotherapy faces a significant challenge in the form of treatment resistance, posing a major hurdle to its effectiveness. Studies have shown that approximately 30% of nonsmall cell lung cancer (NSCLC) patients exhibit resistance to initial immunotherapy, whether utilizing immune checkpoint inhibitors (ICI) alone or in combination with another ICI (7-10). Shao et al. conducted a review to explore the mechanisms underlying immunotherapy resistance and outlined recent breakthroughs in nanomedicine designed to combat this resistance. Tumor heterogeneity and complexity, characterized by intricate metabolic, inflammatory, and neovascular pathways, remain poorly understood yet prevalent contributors to immunotherapy resistance (11). Currently, immunotherapy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.